Ardhia Fefrine Indarta
Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Beta-1,3/1,6-D-Glucan Extracted from Ganoderma lucidum as Adjunct Therapy in Ulcerative Colitis: A Case Series Saskia Aziza Nursyirwan; Marcellus Simadibrata; Rabbinu Rangga Pribadi; Virly Nanda Muzelina; Hasan Maulahela; Amanda Pitarini Utari; Enrik John Aguila; Ardhia Fefrine Indarta
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 27, No 2 (2026): VOLUME 27, NUMBER 2, August, 2026
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2722026204-211

Abstract

The management of ulcerative colitis is primarily focused on the prevention of complications, remission sustenance, and enhancement of overall quality of life. However, long-term use of various pharmacological therapies can be associated with several side effects, including myelosuppression, hepatitis, lupus-like syndrome, and an increased risk of malignancy. These limitations have led to the search for safer therapeutic options, including bioactive compounds such as Beta-1,3/1,6-D-Glucan with immunomodulatory properties. Ganoderma lucidum contains Beta-1,3/1,6-D-Glucan as a principal bioactive compound extracted from its mycelium. Despite the broad therapeutic properties, exploration into its role specifically for ulcerative colitis patients remains scarce. Therefore, this case series aimed to explore the potential role of Beta-1,3/1,6-D-Glucan derived from Mycelium extract of Ganoderma lucidum in managing ulcerative colitis.